The SUNLIGHT study

The SUNLIGHT study holds significant importance in the field of colorectal cancer, specifically in the third-line treatment setting. It is the first study to compare two active regimens in this particular context. The study investigated the addition of bevacizumab to the oral combination of trifluridine and tipiracil in patients with refractory metastatic colorectal cancer.

Prof Dr Josep Tabernero, medical oncologist at the Vall d’Hebron Institute of Oncology and the Principal Investigator of the SUNLIGHT study, along with Prof Dr Eric Van Cutsem, a digestive oncologist at UZ Leuven and co-author, engage in a discussion to delve into the data and findings of the study. During the discussion, they not only analyse the study data but also explore the potential impact that the SUNLIGHT study will have on daily clinical practice

With the educational support of: